Table 3.

Clinical characteristics of patients who received osimertinib at the 3rd Xiangya Hospital.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8
Age at osimertinib treatment (years)	73	49	57	71	48	56	81	55
Sex	Male	Female	Male	Female	Male	Male	Female	Female
Diagnosis	Adenocarcinoma of right lung	Bronchial adenocarcinoma	Adenocarcinoma of right lung	Adenocarcinoma of left lung	Adenocarcinoma of right lung	Lung cancer*	Lung cancer*	Lung cancer*
Duration of cancer history	1 month	4 months	12 months	12 months	20 months	1 months	10 months	8 months
Complications	Benign prostatic hyperplasia	/	COPD	Hypertension	CKD; hypertension	/	Postoperative colon cancer; gallstone; remote cerebral infarction	/
Drug combination	Tiotropium bromide, tamsulosin, finasteride	/	Morphine, ampeptide elemente	Tramadol, celecoxib	Ulbenemax, mosapride, calcium malate, montelukast	/	Mecobalamin, trimetazidine, magnesium potassium aspartate, atorvastatin, aspirin	/
Relative gene	Undetected	EGFR (–)	EGFR (+)	EGFR (+)	EGFR (+)	Undetected	EGFR (+)	EGFR (–)
Metastasis site	Adrenal gland; bone; mediastinal lymph nodes; pleura; right subclavian lymph nodes	Lung; pleura	Mediastinal lymph nodes; right subclavian lymph nodes	Bone; liver	Lymph nodes; pericardium; pleura; enterocoelia	Bone; lung	No metastasis	Adrenal gland; bone; brain
Relative gene	Undetected	EGFR (–)	EGFR (+)	EGFR (+)	EGFR (+)	Undetected	EGFR (+)	EGFR (–)
Start date of osimertinib treatment	2016/12/28	2019/1/29	2019/12/10	2019/6/20	2019/10/28	2020/4/15	2020/4/22	2019/10/13
Follow-up time	5 months	6 months	2 months	14 months	7 months	1 months	5 months	7 months

^*= Without pathological diagnosis; / = Not mentioned in the electronic health records.